Gilead Sciences has filed a patent for a non-coding sequence of DNA that can be used to treat viral infections. The sequence contains a specific motif and can be used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors. The patent claims have been canceled. GlobalData’s report on Gilead Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Gilead Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Gilead Sciences, Peptide pharmacophores was a key innovation area identified from patents. Gilead Sciences's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of viral infections using a non-coding dna sequence

Source: United States Patent and Trademark Office (USPTO). Credit: Gilead Sciences Inc

A recently filed patent (Publication Number: US20230310594A1) describes a method for treating viral infections in patients. The method involves administering a specific non-coding sequence of deoxyribonucleic acids (DNA) to the patient. The sequence is CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC CCTAGGGGTT ACCACCTTCA TTGGAAAACG TTCTTCGGGG CGTTCTTAGG TGGTAACC (SEQ ID NO:5).

The patent claims specify various aspects of the method. Claim 22 states that the method can be used to treat any viral infection in a patient. Claim 23 and 24 specify that the method is effective for treating latent infections and retroviral infections, respectively. Claim 26 focuses on HIV-1 infections, while claim 27 emphasizes its effectiveness against latent HIV-1 infections.

The length of the non-coding sequence of DNA is addressed in claim 28 and 29. It can be up to 200 nucleotides long, but in this specific method, it is 116 nucleotides long.

The patent also discusses the administration of the non-coding sequence of DNA in combination with combination antiretroviral therapy. Claims 30 to 33 describe different ways in which the non-coding sequence of DNA can be administered in conjunction with combination antiretroviral therapy, including simultaneous administration, alternating administration, and successive administration.

Overall, this patent presents a method for treating viral infections, particularly HIV-1 infections, using a specific non-coding sequence of DNA. The method shows potential for treating both latent and retroviral infections. The patent also highlights the possibility of combining this treatment with existing combination antiretroviral therapy, which could potentially enhance the effectiveness of the treatment.

To know more about GlobalData’s detailed insights on Gilead Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies